The development of STING agonists for cancer has been beset by safety issues and discontinued programmes, but Daiichi Sankyo is hoping a new antibody-drug conjugate (ADC) could succeed where others ...

Daiichi Sankyo Company (TSE:4568) has been drifting lower this year, even after solid revenue and profit growth. This has left the stock meaningfully below past highs and prompted investors to revisit ...

Enhertu, a targeted cancer therapy from partners AstraZeneca and Daiichi Sankyo, may now be used as a first-line treatment for advanced cases of breast cancer, making it the first new approved ...

AstraZeneca and Daiichi Sankyo got U.S. approval to expand the label of their jointly developed Enhertu drug in combination with another medicine as an initial treatment for a type of breast cancer.

Lunit and Daiichi Sankyo collaborate to integrate AI-powered digital pathology for biomarker discovery in oncology programs, enhancing translational research and patient stratification. Lunit SCOPE ...

Daiichi Sankyo (TSE: 4568) will present new breast cancer clinical research across its DXd antibody drug conjugate (ADC) portfolio from more than 30 abstracts at the 2025 San Antonio Breast Cancer ...

Daiichi Sankyo released its Q4 2025 earnings, revealing significant growth across several financial metrics. The company’s revenue surged by 17.8% year-over-year to 1,886.3 billion yen, while core ...

Daiichi Sankyo, an innovative global healthcare company, announced that the first patient has been dosed in a first-inhuman phase 1 trial evaluating DS3610 in patients with advanced, metastatic or ...

Daiichi Sankyo Co., Ltd. (TYO:4568) presented its Q2 FY2025 financial results on October 31, 2025, revealing a mixed performance with strong revenue growth but significant profit declines. The company ...

AstraZeneca Plc (NASDAQ:AZN) and Daiichi Sankyo on Monday released high-level results from the TROPION-Breast02 Phase 3 trial. The trial is evaluating Datroway (datopotamab deruxtecan) versus the ...

Daiichi Sankyo, an innovative global healthcare company, has established Daiichi Sankyo Research Institute in San Diego, representing the third research institute established outside of the company’s ...

TOKYO & BASKING RIDGE, N.J., October 02, 2025--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) has established Daiichi Sankyo Research Institute in San Diego, representing the third research institute ...